These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

426 related articles for article (PubMed ID: 34855926)

  • 1. Diversity and heterogeneity of immune states in non-small cell lung cancer and small cell lung cancer.
    Rice SJ; Belani CP
    PLoS One; 2021; 16(12):e0260988. PubMed ID: 34855926
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab.
    Liu J; Li S; Zhang S; Liu Y; Ma L; Zhu J; Xin Y; Wang Y; Yang C; Cheng Y
    J Clin Lab Anal; 2019 Oct; 33(8):e22964. PubMed ID: 31282096
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High pretreatment neutrophil-lymphocyte ratio predicts recurrence and poor prognosis for combined small cell lung cancer.
    Shao N; Cai Q
    Clin Transl Oncol; 2015 Oct; 17(10):772-8. PubMed ID: 26243392
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preoperative systemic immune-inflammation index predicts prognosis and guides clinical treatment in patients with non-small cell lung cancer.
    Yan X; Li G
    Biosci Rep; 2020 Mar; 40(3):. PubMed ID: 32175568
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The predictive effect of the systemic immune-inflammation index for patients with small-cell lung cancer.
    Wang D; Guo D; Shi F; Zhu Y; Li A; Kong L; Teng F; Yu J
    Future Oncol; 2019 Oct; 15(29):3367-3379. PubMed ID: 31424272
    [No Abstract]   [Full Text] [Related]  

  • 6. Systemic immune-inflammation index changes predict outcome in stage III non-small-cell lung cancer patients treated with concurrent chemoradiotherapy.
    Huang T; Zhang H; Zhao Y; Li Y; Wang G; Zhang Y; Guo D; Ji S; Sun Z
    Future Oncol; 2021 Jun; 17(17):2141-2149. PubMed ID: 33635094
    [No Abstract]   [Full Text] [Related]  

  • 7. Systemic immune-inflammation index predicting chemoradiation resistance and poor outcome in patients with stage III non-small cell lung cancer.
    Tong YS; Tan J; Zhou XL; Song YQ; Song YJ
    J Transl Med; 2017 Oct; 15(1):221. PubMed ID: 29089030
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hemoglobin, albumin, lymphocyte, and platelet score and neutrophil-to-lymphocyte ratio are novel significant prognostic factors for patients with small-cell lung cancer undergoing chemotherapy.
    Yang N; Han X; Yu J; Shu W; Qiu F; Han J
    J Cancer Res Ther; 2020 Sep; 16(5):1134-1139. PubMed ID: 33004760
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Are pretreatment neutrophil-lymphocyte ratio and platelet-lymphocyte ratio useful in predicting the outcomes of patients with small-cell lung cancer?
    Deng M; Ma X; Liang X; Zhu C; Wang M
    Oncotarget; 2017 Jun; 8(23):37200-37207. PubMed ID: 28380461
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab.
    Diem S; Schmid S; Krapf M; Flatz L; Born D; Jochum W; Templeton AJ; Früh M
    Lung Cancer; 2017 Sep; 111():176-181. PubMed ID: 28838390
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lung immune prognostic index as a prognostic factor in patients with small cell lung cancer.
    Sonehara K; Tateishi K; Komatsu M; Yamamoto H; Hanaoka M
    Thorac Cancer; 2020 Jun; 11(6):1578-1586. PubMed ID: 32286017
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neutrophil-Lymphocyte Ratio Is a Prognostic Marker in Patients with Locally Advanced (Stage IIIA and IIIB) Non-Small Cell Lung Cancer Treated with Combined Modality Therapy.
    Scilla KA; Bentzen SM; Lam VK; Mohindra P; Nichols EM; Vyfhuis MA; Bhooshan N; Feigenberg SJ; Edelman MJ; Feliciano JL
    Oncologist; 2017 Jun; 22(6):737-742. PubMed ID: 28533476
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The value of blood biomarkers of progression and prognosis in ALK-positive patients with non-small cell lung cancer treated with crizotinib.
    Yang Y; Xu H; Yang G; Yang L; Li J; Wang Y
    Asia Pac J Clin Oncol; 2020 Feb; 16(1):63-69. PubMed ID: 31721468
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Are neutrophil/lymphocyte and platelet/lymphocyte rates in patients with non-small cell lung cancer associated with treatment response and prognosis?
    Unal D; Eroglu C; Kurtul N; Oguz A; Tasdemir A
    Asian Pac J Cancer Prev; 2013; 14(9):5237-42. PubMed ID: 24175807
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic utility of blood inflammation biomarkers before and after treatment on the survival of patients with locally advanced non-small cell lung cancer undergoing stereotactic body radiotherapy.
    Fang F; Jia Z; Xie H; Cao Y; Zhu X; Yang XY; Guo X; Zhang H
    Clin Respir J; 2024 May; 18(5):e13749. PubMed ID: 38685745
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High systemic immune-inflammation index predicts poor prognosis in advanced lung adenocarcinoma patients treated with EGFR-TKIs.
    Deng C; Zhang N; Wang Y; Jiang S; Lu M; Huang Y; Ma J; Hu C; Hou T
    Medicine (Baltimore); 2019 Aug; 98(33):e16875. PubMed ID: 31415428
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High neutrophil-to-lymphocyte ratios confer poor prognoses in patients with small cell lung cancer.
    Liu D; Huang Y; Li L; Song J; Zhang L; Li W
    BMC Cancer; 2017 Dec; 17(1):882. PubMed ID: 29268698
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of baseline hemoglobin-to-red blood cell distribution width ratio in small cell lung cancer: A retrospective analysis.
    Wu F; Yang S; Tang X; Liu W; Chen H; Gao H
    Thorac Cancer; 2020 Apr; 11(4):888-897. PubMed ID: 32087605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive value of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in non-small cell lung cancer patients treated with immune checkpoint inhibitors: A meta-analysis.
    Zhang N; Jiang J; Tang S; Sun G
    Int Immunopharmacol; 2020 Aug; 85():106677. PubMed ID: 32531712
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pretreatment Immune Parameters Predict for Overall Survival and Toxicity in Early-Stage Non-Small-Cell Lung Cancer Patients Treated With Stereotactic Body Radiation Therapy.
    Shaverdian N; Veruttipong D; Wang J; Schaue D; Kupelian P; Lee P
    Clin Lung Cancer; 2016 Jan; 17(1):39-46. PubMed ID: 26372098
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.